Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Inclusion Criteria: * Male and female patients ≥ 18 years of age * An acute onset of at least 3 of the following signs and symptoms (new or worsening): 1. Cough 2. Production of purulent sputum 3. Shortness of breath (dyspnea) 4. Chest pain due to pneumonia * At least 1 of the following: 1. Fever 2. Hypothermia 3. Presence of pulmonary rales and/or evidence of pulmonary consolidation * PORT Risk Class II, III, or IV * Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study * Not received any systemic antibiotics during the prior 7 days Exclusion Criteria: * Ventilator-associated pneumonia * Known anatomical or pathological bronchial obstruction or a history of bronchiectasis or documented severe chronic obstructive pulmonary disease * Hospitalization within 90 days or residence in a long-term care facility within 30 days prior to the onset of symptoms * Fungal pneumonia * Pneumocystis jiroveci pneumonia * Aspiration pneumonia * Other non-infectious causes of pulmonary infiltrates * Primary or metastatic lung cancer * Cystic fibrosis * Active or suspected tuberculosis * HIV or myasthenia gravis